跳转至内容
Merck
CN

453R-2

p53 (EP9) Rabbit Monoclonal Primary Antibody

登录 查看组织和合同定价。

选择尺寸

关于此项目

NACRES:
NA.41
UNSPSC Code:
12352203

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

biological source

rabbit

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

EP9, monoclonal

description

For In Vitro Diagnostic Use in Select Regions (See Chart)

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate (453R-24)
vial of 0.1 mL concentrate Research Use Only (453R-24-RUO)
vial of 0.5 mL concentrate (453R-25)
bottle of 1.0 mL predilute ready-to-use (453R-27)
vial of 1.0 mL concentrate (453R-26)
vial of 1.0 mL concentrate Research Use Only (453R-26-RUO)
vial of 1.0 mL pre-dilute Research Use Only (453R-27-RUO)
bottle of 7.0 mL predilute ready-to-use (453R-28)
vial of 7.0 mL pre-dilute ready-to-use Research Use Only (453R-28-RUO)

manufacturer/tradename

Cell Marque®

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:200 (concentrate)

control

breast carcinoma ((breast ductal carcinoma in-situ)), colorectal carcinoma, ovarian carcinoma ((ovarian serous carcinoma)), urothelial carcinoma

shipped in

wet ice

storage temp.

2-8°C

visualization

nuclear

Quality Level

100
500

Gene Information

human ... TP53(7157)

相关类别

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
p53 Positive Control Slides, Product No. 453S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Analysis Note

United States - IVD
Canada - IVD
European Union - IVD
Japan - RUO

General description

Anti-p53 tumor suppressor protein antibody recognizes a 53 kDa phosphoprotein, identified as p53 suppressor gene product. It reacts with the mutant as well as wild type p53, although significant accumulation of the mutant form of p53 protein due to longer half-life is the basis for the test using the IHC technique. Nuclear staining with this antibody has been shown in breast carcinoma, lung carcinoma, colorectal carcinoma, and urothelial carcinoma.

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

Download the latest released IFU
Note: This IFU may not apply to your specific product lot

Legal Information

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany

未找到合适的产品？  

试试我们的产品选型工具.

存储类别

12 - Non Combustible Liquids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

监管及禁止进口产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000249694
0000262585
0000264388
0000262585
0000249694

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Diagnostic Immunohistochemistry (Masson Publishing), Page 701-Page 702 (2006)
David J Dabbs et al.
The American journal of surgical pathology, 37(7), e1-11 (2013-06-14)
Lobular neoplasia (LN) is a term that encompasses both lobular carcinoma in situ and atypical lobular hyperplasia. These lesions have been shown to constitute both risk indicators and nonobligate precursors of invasive breast cancer, they are relatively uncommon, and are
J K McKenney et al.
The American journal of surgical pathology, 25(8), 1074-1078 (2001-07-28)
Distinction of urothelial carcinoma in situ (CIS) from reactive atypia on the basis of morphology alone may be difficult in some cases. Because this distinction is therapeutically and prognostically critical, we attempted to determine if an immunohistochemical panel would help
O Caffo et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2(9), 1591-1599 (1996-09-01)
p21 protein (p21) inhibitor of cyclin-dependent kinases is a critical downstream effector in the p53-specific pathway of growth control and can also be induced by p53-independent pathways in relation to terminal differentiation. We investigated p21 immunoreactivity in 261 breast carcinomas
D C Quinlan et al.
Cancer research, 52(17), 4828-4831 (1992-09-01)
Mutations in the gene coding for the p53 tumor suppressor protein are common in a variety of human cancers. To assess the role of a putative mutated p53 protein in human lung cancer, a monoclonal antibody recognizing it was used
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持